It has been hypothesized that epidermal growth factor receptor and CK5/6 are positive predictive markers of the triple-negative breast cancer (TNBC) response to everolimus [26], although our data do not support this hypothesis. This evidence concerns the gene EGFR and triple-negative breast carcinoma.